| Year |
Citation |
Score |
| 2024 |
Joseph R, Dasari SK, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Kim MS, Corvigno S, Foster K, Hanjra P, ... ... Lopez-Berestein G, et al. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. International Journal of Molecular Sciences. 25. PMID 38279277 DOI: 10.3390/ijms25021278 |
0.362 |
|
| 2023 |
Szymanowski W, Szymanowska A, Bielawska A, Lopez-Berestein G, Rodriguez-Aguayo C, Amero P. Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges. Cancers. 15. PMID 37958473 DOI: 10.3390/cancers15215300 |
0.306 |
|
| 2023 |
Dasari SK, Joseph R, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, et al. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. International Journal of Molecular Sciences. 24. PMID 36835335 DOI: 10.3390/ijms24043915 |
0.366 |
|
| 2020 |
Noh K, Bach DH, Choi HJ, Kim MS, Wu SY, Pradeep S, Ivan C, Cho MS, Bayraktar E, Rodriguez-Aguayo C, Dasari SK, Stur E, Mangala LS, Lopez-Berestein G, Sood AK. The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene. PMID 33149280 DOI: 10.1038/s41388-020-01517-3 |
0.36 |
|
| 2020 |
Elsayed AM, Amero P, Salama SA, Abdelaziz AH, Lopez-Berestein G, Rodriguez-Aguayo C. Back to the Future: Rethinking the Great Potential of lncRNA for Optimizing Chemotherapeutic Response in Ovarian Cancer. Cancers. 12. PMID 32854207 DOI: 10.3390/Cancers12092406 |
0.362 |
|
| 2020 |
Lara OD, Bayraktar E, Amero P, Ma S, Ivan C, Hu W, Wang Y, Mangala LS, Dutta P, Bhattacharya P, Ashizawa AT, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AK. Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. Oncotarget. 11: 2819-2833. PMID 32754300 DOI: 10.18632/Oncotarget.27667 |
0.426 |
|
| 2020 |
Miyake TM, Pradeep S, Bayraktar E, Stur E, Handley KF, Wu SY, Rodriguez-Aguayo C, Lee JS, Lopez-Berestein G, Coleman RL, Sood AK. NRG1/ERBB3 pathway activation induces acquired resistance to XPO1 inhibitors. Molecular Cancer Therapeutics. PMID 32499298 DOI: 10.1158/1535-7163.Mct-19-0977 |
0.454 |
|
| 2020 |
Attia YM, Shouman SA, Salama SA, Ivan C, Elsayed AM, Amero P, Rodriguez-Aguayo C, Lopez-Berestein G. Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer. International Journal of Molecular Sciences. 21. PMID 32340192 DOI: 10.3390/Ijms21082974 |
0.466 |
|
| 2020 |
Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, ... ... Lopez-Berestein G, et al. Corrigendum to 'Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer' [EBioMedicine 38 (2018) 100-112]. Ebiomedicine. 52: 102630. PMID 31972470 DOI: 10.1016/J.Ebiom.2020.102630 |
0.329 |
|
| 2020 |
El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cellular Signalling. 109539. PMID 31935430 DOI: 10.1016/J.Cellsig.2020.109539 |
0.452 |
|
| 2020 |
Ma S, Mangala LS, Hu W, Bayaktar E, Hu W, Jennings NB, Coleman RL, Lopez-Berestein G, Sood AK. Abstract 6331: Cloaking VEGF in small extracellular vesicles as a cause of adaptive resistance to anti-VEGF therapy Cancer Research. 80: 6331-6331. DOI: 10.1158/1538-7445.Am2020-6331 |
0.354 |
|
| 2019 |
Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, et al. miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. Cell Reports. 29: 4389-4406.e10. PMID 31875548 DOI: 10.1016/J.Celrep.2019.11.085 |
0.417 |
|
| 2019 |
Oncul S, Amero P, Rodriguez-Aguayo C, Calin GA, Sood AK, Lopez-Berestein G. Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum. Rna Biology. 1-12. PMID 31847695 DOI: 10.1080/15476286.2019.1702283 |
0.401 |
|
| 2019 |
Xu X, Wang Y, Mojumdar K, Zhou Z, Jeong KJ, Mangala LS, Yu S, Tsang YH, Rodriguez-Aguayo C, Lu Y, Lopez-Berestein G, Sood AK, Mills GB, Liang H. A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. The Journal of Clinical Investigation. PMID 31682236 DOI: 10.1172/Jci123396 |
0.389 |
|
| 2019 |
Yang H, Shu Z, Jiang Y, Mao W, Pang L, Redwood A, Jeter-Jones SL, Jennings NB, Ornelas A, Zhou J, Rodriguez-Aguayo C, Bartholomeusz G, Iles LR, Zacharias NM, Millward SW, ... Lopez-Berestein G, et al. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31391192 DOI: 10.1158/1078-0432.Ccr-18-3448 |
0.455 |
|
| 2019 |
Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, et al. Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene. PMID 31289363 DOI: 10.1038/S41388-019-0862-Y |
0.378 |
|
| 2019 |
Park YY, Yun Jung S, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Bae Kim S, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. PMID 31063534 DOI: 10.1093/Carcin/Bgz062 |
0.336 |
|
| 2019 |
Azam SH, Porrello A, Harrison EB, Leslie PL, Liu X, Waugh TA, Belanger A, Mangala LS, Lopez-Berestein G, Wilson HL, McCann JV, Kim WY, Sood AK, Liu J, Dudley AC, et al. Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis. Oncogene. PMID 30918328 DOI: 10.1038/S41388-019-0786-6 |
0.427 |
|
| 2019 |
Gonzalez-Villasana V, Rashed MH, Gonzalez-Cantú Y, Bayraktar R, Menchaca-Arredondo JL, Vazquez-Guillen JM, Rodriguez-Padilla C, Lopez-Berestein G, Resendez-Perez D. Presence of Circulating miR-145, miR-155, and miR-382 in Exosomes Isolated from Serum of Breast Cancer Patients and Healthy Donors. Disease Markers. 2019: 6852917. PMID 30891102 DOI: 10.1155/2019/6852917 |
0.319 |
|
| 2019 |
Tekedereli I, Akar U, Alpay SN, Lopez-Berestein G, Ozpolat B. Autophagy is Required to Regulate Mitochondria Renewal, Cell Attachment, and All-trans-Retinoic Acid-Induced Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society For Environmental Toxicology and Cancer. 38: 13-20. PMID 30806286 DOI: 10.1615/Jenvironpatholtoxicoloncol.2018027885 |
0.355 |
|
| 2019 |
Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, ... ... Lopez-Berestein G, et al. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. Ebiomedicine. PMID 30655206 DOI: 10.1016/J.Ebiom.2018.11.045 |
0.381 |
|
| 2019 |
Duzagac F, Lopez-Berestein G, Kanlikilicer P, Rodriguez-Aguoya C, Cardenas-Zuniga R, Guven U, Oktem G, Ozpolat B. Abstract 3686: Regulatory role cancer stem cells (CSCs)-derived exosomal miRNAs in ovarian cancer growth and progression Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3686 |
0.394 |
|
| 2019 |
Rodriguez-Aguayo C, Bayraktar E, Mangala LS, Ivan C, Lopez-Berestein G, Sood AK. Abstract 3579: Long non-coding RNA ADAMTS9-AS2 inhibits ovarian tumor growth via Annexin A1 Cancer Research. 79: 3579-3579. DOI: 10.1158/1538-7445.Sabcs18-3579 |
0.429 |
|
| 2019 |
Kanlikilicer P, El-Arabey AA, Denizli M, Bayraktar R, Ozpolat B, Lopez-Berestein G, Salama SA, Abd-Allah AR. Abstract 1981: M2-macrophage derived exosomes mediates tumor progression via GATA3-IL-4-IL-13 axis in ovarian cancer Cancer Research. 79: 1981-1981. DOI: 10.1158/1538-7445.Sabcs18-1981 |
0.39 |
|
| 2019 |
Ma S, McGuire MH, Stur E, Bayraktar E, Villar-Prados A, Wu SY, Yokoi A, Dasari SK, Rodriguez-Aguayo C, Liu J, Lopez-Berestein G, Sood AK. Abstract LB-311: Exosomal gain-of-function p53 protein promotes cancer-associated phenotype Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-311 |
0.429 |
|
| 2019 |
Mokhlis HA, Kahraman N, Baydogan S, Abdel-Aziz AH, Ashour A, Ivan C, Lopez-Berestein G, Ozpolat B. Abstract 4262: MiR-873 is the master regulator of autophagy genes through a novel negative feedback mechanism mediated by Elongation factor 2 kinase (eEF-2K) and suppresses tumor growth and progression of triple negative breast cancer Cancer Research. 79: 4262-4262. DOI: 10.1158/1538-7445.Am2019-4262 |
0.418 |
|
| 2019 |
Guven U, Mokhlis HA, Kahraman N, Ivan C, Duzagac F, Lopez-Berestein G, Oktem G, Ozpolat B. Abstract 2591: miR-193b is a novel regulator of Inhibition of Notch signaling by for targeting cancer stem cell and tumor microenvironment Cancer Research. 79: 2591-2591. DOI: 10.1158/1538-7445.Am2019-2591 |
0.466 |
|
| 2018 |
Mokhlis HA, Bayraktar R, Kabil NN, Caner A, Kahraman N, Rodriguez-Aguayo C, Zambalde EP, Sheng J, Karagoz K, Kanlikilicer P, Abdel Aziz AAH, Abdelghany TM, Ashour AA, Wong S, Gatza ML, ... ... Lopez-Berestein G, et al. The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers. Molecular Therapy. Nucleic Acids. 14: 301-317. PMID 30654191 DOI: 10.1016/J.Omtn.2018.11.019 |
0.38 |
|
| 2018 |
Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Yang SM, Maloney DJ, et al. Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein BRD4. Molecular Cancer Therapeutics. PMID 30420565 DOI: 10.1158/1535-7163.Mct-18-0365 |
0.343 |
|
| 2018 |
Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, ... ... Lopez-Berestein G, et al. PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Molecular Cancer Therapeutics. PMID 30305341 DOI: 10.1158/1535-7163.Mct-17-1050 |
0.425 |
|
| 2018 |
Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Artholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC. Paclitaxel Sensitivity of Ovarian Cancer can be enhanced by knocking down Pairs of Kinases that regulate MAP4 Phosphorylation and Microtubule Stability. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30084832 DOI: 10.1158/1078-0432.Ccr-18-0504 |
0.331 |
|
| 2018 |
Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, ... ... Lopez-Berestein G, et al. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nature Communications. 9: 2923. PMID 30050129 DOI: 10.1038/S41467-018-04987-Y |
0.459 |
|
| 2018 |
González-González A, Muñoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jiménez G, Verma A, Ramírez A, Qian W, Chen W, Kozielski AJ, Elemento O, Martin-Salvago MD, Luque RJ, ... ... Lopez-Berestein G, et al. Activating transcription factor 4 modulates TGFβ-induced aggressiveness in triple negative breast cancer via SMAD2/3/4 and mTORC2 signaling. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30012564 DOI: 10.1158/1078-0432.Ccr-17-3125 |
0.391 |
|
| 2018 |
Kabil N, Bayraktar R, Kahraman N, Mokhlis HA, Calin GA, Lopez-Berestein G, Ozpolat B. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer. Breast Cancer Research and Treatment. PMID 29971628 DOI: 10.1007/S10549-018-4847-2 |
0.422 |
|
| 2018 |
Shahzad MMK, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, et al. Stress effects on FosB and interleukin-8 ()-driven ovarian cancer growth and metastasis. The Journal of Biological Chemistry. 293: 10041. PMID 29959278 DOI: 10.1074/Jbc.Aac118.004299 |
0.368 |
|
| 2018 |
Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, ... ... Lopez-Berestein G, et al. ATP11B mediates platinum resistance in ovarian cancer. The Journal of Clinical Investigation. PMID 29809169 DOI: 10.1172/Jci122301 |
0.448 |
|
| 2018 |
Bayraktar R, Ivan C, Bayraktar E, Kanlikilicer P, Kabil N, Kahraman N, Mokhlis HA, Karakas D, Rodriguez-Aguayo C, Arslan A, Sheng J, Wong ST, Lopez-Berestein G, Calin GA, Ozpolat B. Dual suppressive effect of microRNA-34a on the FOXM1/eEF2-kinase axis regulates triple-negative breast cancer growth and invasion. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29748184 DOI: 10.1158/1078-0432.Ccr-17-1959 |
0.346 |
|
| 2018 |
Zhang P, Xiao Z, Wang S, Zhang M, Wei Y, Hang Q, Kim J, Yao F, Rodriguez-Aguayo C, Ton BN, Lee M, Wang Y, Zhou Z, Zeng L, Hu X, ... ... Lopez-Berestein G, et al. ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Reports. 23: 823-837. PMID 29669287 DOI: 10.1016/J.Celrep.2018.03.078 |
0.444 |
|
| 2018 |
Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemerrle M, Gharpure KM, Rupaimoole R, Previs R, Wu SY, Pradeep S, Xu X, ... ... Lopez-Berestein G, et al. Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction. Cancer Research. PMID 29661830 DOI: 10.1158/0008-5472.Can-16-1701 |
0.334 |
|
| 2018 |
Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, ... ... Lopez-Berestein G, et al. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nature Communications. 9: 476. PMID 29396402 DOI: 10.1038/S41467-017-02811-7 |
0.404 |
|
| 2018 |
Lara OD, Rodriquez-Aguayo C, Bayrakter E, Amero P, Mangala S, LaFargue C, Tari-Ashizawa A, Lopez-Berestein G, Sood A. Abstract 5786: Grabbing GRB2: The use of liposome-incorporated Grb2 antisense oligonucleotides as a novel therapy in gynecologic malignancies Cancer Research. 78: 5786-5786. DOI: 10.1158/1538-7445.Am2018-5786 |
0.398 |
|
| 2018 |
Amero P, Rodriguez-Aguayo C, Lokesh G, Bayraktar E, Ivan C, Chaudhari R, Zhang S, Volk D, Sood A, Lopez-Berestein G. Development of novel modified aptamers to target Axl receptor in ovarian cancer Annals of Oncology. 29: iii17. DOI: 10.1093/Annonc/Mdy047.029 |
0.378 |
|
| 2017 |
Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. The Journal of Clinical Investigation. PMID 29251630 DOI: 10.1172/Jci95200 |
0.377 |
|
| 2017 |
Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A, Cong Y, Wong H, Qian W, Li Z, Granados-Principal S, ... Lopez-Berestein G, et al. HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. Stem Cell Reports. PMID 29249663 DOI: 10.1016/J.Stemcr.2017.11.010 |
0.451 |
|
| 2017 |
Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, ... ... Lopez-Berestein G, et al. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Molecular Therapy. Nucleic Acids. 9: 251-262. PMID 29246304 DOI: 10.1016/J.Omtn.2017.06.023 |
0.48 |
|
| 2017 |
Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK. RNA interference-based therapy and its delivery systems. Cancer Metastasis Reviews. PMID 29243000 DOI: 10.1007/S10555-017-9717-6 |
0.336 |
|
| 2017 |
Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, ... ... Lopez-Berestein G, et al. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Reports. 21: 2785-2795. PMID 29212026 DOI: 10.1016/J.Celrep.2017.11.020 |
0.357 |
|
| 2017 |
Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Demarzo A, Sood AK, Zhang L, Dang CV. MYC targeted long non-coding RNA DANCR promotes cancer in part by reducing p21 levels. Cancer Research. PMID 29180471 DOI: 10.1158/0008-5472.Can-17-0815 |
0.475 |
|
| 2017 |
Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, ... ... Lopez-Berestein G, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. The Journal of Clinical Investigation. PMID 29130936 DOI: 10.1172/Jci91553 |
0.397 |
|
| 2017 |
Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, Chen X, Ivan C, Rodriguez-Aguayo C, Hu W, Lopez-Berestein G, et al. Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene. PMID 29059175 DOI: 10.1038/Onc.2017.348 |
0.431 |
|
| 2017 |
Rodriguez-Aguayo C, Monroig PDC, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Mitra R, Sood AK, Calin GA, Lopez-Berestein G. Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discovery. 3: 17029. PMID 28904816 DOI: 10.1038/celldisc.2017.29 |
0.32 |
|
| 2017 |
Sood AK, Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu S, Mangala LS, ... ... Lopez-Berestein G, et al. Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28855350 DOI: 10.1158/1078-0432.Ccr-17-0647 |
0.332 |
|
| 2017 |
Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, ... ... Lopez-Berestein G, et al. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nature Communications. 8: 310. PMID 28827520 DOI: 10.1038/S41467-017-00411-Z |
0.408 |
|
| 2017 |
Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, ... ... Lopez-Berestein G, et al. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. Jci Insight. 2. PMID 28814667 DOI: 10.1172/Jci.Insight.93076 |
0.418 |
|
| 2017 |
Tseng JH, Bisogna M, Hoang LN, Olvera N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Levine DA, Jelinic P. miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. Scientific Reports. 7: 3614. PMID 28620240 DOI: 10.1038/S41598-017-03972-7 |
0.335 |
|
| 2017 |
Hu Q, Hisamatsu T, Hammerle M, Cho MS, Pradeep S, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Wong ST, Sood AK, Afshar-Kharghan V. Role of platelet-derived Tgfβ1 in the progression of ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28611202 DOI: 10.1158/1078-0432.Ccr-16-3272 |
0.422 |
|
| 2017 |
Rigoutsos I, Lee SK, Nam SY, Anfossi S, Pasculli B, Pichler M, Jing Y, Rodriguez-Aguayo C, Telonis AG, Rossi S, Ivan C, Catela Ivkovic T, Fabris L, Clark PM, Ling H, ... ... Lopez-Berestein G, et al. N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biology. 18: 98. PMID 28535802 DOI: 10.1186/S13059-017-1224-0 |
0.333 |
|
| 2017 |
Rabinowicz N, Mangala LS, Brown KR, Checa-Rodriguez C, Castiel A, Moskovich O, Zarfati G, Trakhtenbrot L, Levy-Barda A, Jiang D, Rodriguez-Aguayo C, Pradeep S, van Praag Y, Lopez-Berestein G, David A, et al. Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. Oncotarget. 27380-27392. PMID 28423708 DOI: 10.18632/Oncotarget.16068 |
0.394 |
|
| 2017 |
Court KA, Hatakeyama H, Wu SY, Lingegowda MS, Rodriguez-Aguayo C, Lopez-Berestein G, Ju-Seog L, Rinaldi C, Juan EJ, Sood AK, Torres-Lugo M. HSP70 inhibition synergistically enhances the effects of magnetic fluid hyperthermia in ovarian cancer. Molecular Cancer Therapeutics. PMID 28223424 DOI: 10.1158/1535-7163.Mct-16-0519 |
0.448 |
|
| 2017 |
Naing A, Lopez-Berestein G, Fu S, Tsimberidou AM, Pant S, Piha-Paul SA, Janku F, Hong DS, Sulovic S, Meng X, Jazaeri AA, Ng CS, Karp DD, Subbiah V, Meric-Bernstam F, et al. EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial. Journal of Clinical Oncology. 35: TPS2604-TPS2604. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps2604 |
0.44 |
|
| 2017 |
Ghazaly EA, Quesne JL, Jiang D, Mangala SL, Chettle J, Rodriguez-Aguayo C, Lopez-Berestein G, Gnanaranjan C, Mura M, Stavraka C, Sood AK, Blagden SP. Abstract B30: The RNA-binding protein LARP1 is a cancer therapeutic target Cancer Research. 77. DOI: 10.1158/1538-7445.Transcontrol16-B30 |
0.448 |
|
| 2017 |
McGuire MH, Herbrich S, Wu S, Wang Y, Rupaimoole R, Yao H, Gharpure K, Lopez-Berestein G, Baggerly K, Sood A. Abstract 5377: Intragenic DNA methylation and increased gene expression: New directions from pan-cancer analysis Cancer Research. 77: 5377-5377. DOI: 10.1158/1538-7445.Am2017-5377 |
0.338 |
|
| 2017 |
Ashizawa AT, Gutierrez-Puente Y, Ford R, Lopez-Berestein G. Abstract 5091: Activity of Bcl-2 antisense therapeutic in aggressive non-Hodgkin's lymphoma Cancer Research. 77: 5091-5091. DOI: 10.1158/1538-7445.Am2017-5091 |
0.328 |
|
| 2017 |
Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Noh K, Filant J, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Bartholomeusz GA, ... ... Lopez-Berestein G, et al. Abstract 473: PRKRA/PACT expression promotes chemoresistance in mucinous ovarian cancer Cancer Research. 77: 473-473. DOI: 10.1158/1538-7445.Am2017-473 |
0.444 |
|
| 2017 |
Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Dorniak PL, ... ... Lopez-Berestein G, et al. Abstract 4144: Role of CTGF in hyperthermia resistance in ovarian and uterine cancers Cancer Research. 77: 4144-4144. DOI: 10.1158/1538-7445.Am2017-4144 |
0.458 |
|
| 2017 |
Yang H, Zhang S, Mao W, Ahmed AA, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Le X, Lu Z, Bast RC. Abstract 3564: Silencing pfkfb2 enhances paclitaxel sensitivity by modulating metabolism of p53 wt ovarian and breast cancer cells and xenografts Cancer Research. 77: 3564-3564. DOI: 10.1158/1538-7445.Am2017-3564 |
0.395 |
|
| 2017 |
Bayraktar E, Rodriguez-Aguayo C, Siddik Z, Lopez-Berestein G. Abstract 2066: Delivery of 2`F-PS2 PTGER3 siRNA-DOPC enhances anti-tumoral activity in cisplatin resistant ovarian cancer model Cancer Research. 77: 2066-2066. DOI: 10.1158/1538-7445.Am2017-2066 |
0.387 |
|
| 2017 |
Kanlikilicer P, Bayraktar R, Rashed M, Aslan B, Calin GA, Sood AK, Lopez-Berestein G. Abstract 1988: Exosome-mediated ovarian cancer tumorigenesis mediated by miR1246/Rb/Cav1 axis Cancer Research. 77: 1988-1988. DOI: 10.1158/1538-7445.Am2017-1988 |
0.363 |
|
| 2017 |
Asik E, Kahraman N, Guray T, Volkan M, Lopez-Berestein G, Ozpolat B. Abstract 1125: Eukaryotic Elongation Factor 2 Kinase (eEF-2K) is a novel therapeutic target in BRCA1+ mutated breast cancer Cancer Research. 77: 1125-1125. DOI: 10.1158/1538-7445.Am2017-1125 |
0.449 |
|
| 2016 |
Bayraktar R, Pichler M, Kanlikilicer P, Ivan C, Bayraktar E, Kahraman N, Aslan B, Oguztuzun S, Ulasli M, Arslan A, Calin G, Lopez-Berestein G, Ozpolat B. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget. PMID 28036267 DOI: 10.18632/Oncotarget.14264 |
0.439 |
|
| 2016 |
Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis R, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, ... ... Lopez-Berestein G, et al. Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27903673 DOI: 10.1158/1078-0432.Ccr-16-1025 |
0.344 |
|
| 2016 |
Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini JC, Ni J, Nakahara R, Wahlig S, Chiba L, Kim SH, Morse J, Pradeep S, ... ... Lopez-Berestein G, et al. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metabolism. 24: 685-700. PMID 27829138 DOI: 10.1016/J.Cmet.2016.10.011 |
0.459 |
|
| 2016 |
Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Jennings N, ... ... Lopez-Berestein G, et al. Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Reports. 17: 1621-1631. PMID 27806300 DOI: 10.1016/J.Celrep.2016.10.020 |
0.433 |
|
| 2016 |
Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GL, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, ... ... Lopez-Berestein G, et al. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. Jci Insight. 1: e87754. PMID 27777972 DOI: 10.1172/Jci.Insight.87754 |
0.4 |
|
| 2016 |
Kanlikilicer P, Saber M, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, Bayraktar E, Pichler M, Ozpolat B, Calin GA, Sood AK, ... Lopez-Berestein G, et al. Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Research. PMID 27742688 DOI: 10.1158/0008-5472.Can-16-0714 |
0.434 |
|
| 2016 |
Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA. microRNA Therapeutics in Cancer - An Emerging Concept. Ebiomedicine. PMID 27720213 DOI: 10.1016/J.Ebiom.2016.09.017 |
0.343 |
|
| 2016 |
Seviour EG, Sehgal V, Mishra D, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Lee JS, Sood AK, Kim MP, Mills GB, Ram PT. Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. Oncogene. PMID 27669434 DOI: 10.1038/Onc.2016.308 |
0.338 |
|
| 2016 |
Harjes U, Bridges E, Gharpure KM, Roxanis I, Sheldon H, Miranda F, Mangala LS, Pradeep S, Lopez-Berestein G, Ahmed A, Fielding B, Sood AK, Harris AL. Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. Oncogene. PMID 27568980 DOI: 10.1038/Onc.2016.256 |
0.329 |
|
| 2016 |
Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, ... Lopez-Berestein G, et al. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell. PMID 27478041 DOI: 10.1016/J.Ccell.2016.06.020 |
0.443 |
|
| 2016 |
Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, et al. ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell. 29: 874-888. PMID 27300436 DOI: 10.1016/J.Ccell.2016.04.016 |
0.379 |
|
| 2016 |
Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, et al. Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Reports. PMID 27160903 DOI: 10.1016/J.Celrep.2016.04.034 |
0.459 |
|
| 2016 |
Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, ... ... Lopez-Berestein G, et al. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. The Journal of Clinical Investigation. PMID 27064283 DOI: 10.1172/Jci85086 |
0.383 |
|
| 2016 |
Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, ... ... Lopez-Berestein G, et al. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications. 7: 11169. PMID 27041221 DOI: 10.1038/Ncomms11169 |
0.337 |
|
| 2016 |
Rytelewski M, Vareki SM, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget. PMID 26959114 DOI: 10.18632/Oncotarget.7883 |
0.412 |
|
| 2016 |
Dwivedi SK, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P, Calin GA, Lopez-Berestein G, Sood AK, Bhattacharya R. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. PMID 26918603 DOI: 10.18632/Oncotarget.7618 |
0.33 |
|
| 2016 |
Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK. miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discovery. 6: 235-46. PMID 26865249 DOI: 10.1158/2159-8290.Cd-15-0893 |
0.373 |
|
| 2016 |
Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot CV, et al. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene. 35: 801. PMID 26865225 DOI: 10.1038/Onc.2015.177 |
0.357 |
|
| 2016 |
Han HD, Cho YJ, Cho SK, Byeon Y, Jeon HN, Kim HS, Kim BG, Bae DS, Lopez-Berestein G, Sood AK, Shin BC, Park YM, Lee JW. Linalool-incorporated nanoparticles as a novel anticancer agent for epithelial ovarian carcinoma. Molecular Cancer Therapeutics. PMID 26861249 DOI: 10.1158/1535-7163.Mct-15-0733-T |
0.359 |
|
| 2016 |
Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, ... ... Lopez-Berestein G, et al. Role of Increased n-acetylaspartate Levels in Cancer. Journal of the National Cancer Institute. 108. PMID 26819345 DOI: 10.1093/Jnci/Djv426 |
0.374 |
|
| 2016 |
Rupaimoole R, Ivan C, Yang D, Gharpure KM, Wu SY, Pecot CV, Previs RA, Nagaraja AS, Armaiz-Pena GN, McGuire M, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Huang L, Bar-Eli M, ... ... Lopez-Berestein G, et al. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene. PMID 26725326 DOI: 10.1038/Onc.2015.492 |
0.391 |
|
| 2016 |
Hatakeyama H, Wu SY, Mangala LS, Lopez-Berestein G, Sood AK. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods in Molecular Biology (Clifton, N.J.). 1402: 189-97. PMID 26721492 DOI: 10.1007/978-1-4939-3378-5_15 |
0.404 |
|
| 2016 |
Zhang X, Lopez-Berestein G, Sood AK, Calin GA. Profiling Long Noncoding RNA Expression Using Custom-Designed Microarray. Methods in Molecular Biology (Clifton, N.J.). 1402: 33-41. PMID 26721482 DOI: 10.1007/978-1-4939-3378-5_5 |
0.319 |
|
| 2016 |
Pradeep S, Huang J, Mora E, Wu SY, Li C, Lopez-Berestein G, Jackson D, Sood A. Abstract B68: Erythropoietin stimulates ovarian tumor growth via EphB4. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B68 |
0.444 |
|
| 2016 |
Kanlikilicer P, Rashed MMHS, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Cristian R, Bayraktar E, Picher M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Abstract 763: Exosomal miR-6126 as a novel tumor suppressor in ovarian cancer Cancer Research. 76: 763-763. DOI: 10.1158/1538-7445.Am2016-763 |
0.448 |
|
| 2016 |
Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi H, Stone RL, Cho MS, Nick AM, Lopez-Berestein G, Afshar-Khargan V, Sood AK. Abstract 5048: Platelet FAK is a critical regulator of tumor growth after withdrawal of anti-angiogenic therapy Cancer Research. 76: 5048-5048. DOI: 10.1158/1538-7445.Am2016-5048 |
0.383 |
|
| 2016 |
Bayraktar E, Rodriguez-Aguayo C, Mai J, Ivan C, Chavez-Reyes A, Sood AK, Ferrari M, Shen H, Lopez-Berestein G. Abstract 4668: Silencing PTGER3 enhances chemotherapeutic responses Cancer Research. 76: 4668-4668. DOI: 10.1158/1538-7445.Am2016-4668 |
0.507 |
|
| 2016 |
Wagner MJ, Mitra R, Baze W, Barnhart K, Coleman RL, Lopez-Berestein G, Sood AK. Abstract 2094: Translating EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA) to the clinic Cancer Research. 76: 2094-2094. DOI: 10.1158/1538-7445.Am2016-2094 |
0.315 |
|
| 2016 |
Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Zhang X, Wistuba I, Lopez-Berestein G, Fabbri M, Calin G. Targeting miR-155 to resensitize lung cancer to chemotherapy European Journal of Cancer. 61: S116. DOI: 10.1016/S0959-8049(16)61409-0 |
0.336 |
|
| 2015 |
Bullock MD, Silva AM, Kanlikilicer-Unaldi P, Filant J, Rashed MH, Sood AK, Lopez-Berestein G, Calin GA. Exosomal Non-Coding RNAs: Diagnostic, Prognostic and Therapeutic Applications in Cancer. Non-Coding Rna. 1: 53-68. PMID 29861415 DOI: 10.3390/Ncrna1010053 |
0.388 |
|
| 2015 |
Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NM, Nagaraja AS, Gharpure KM, McGuire M, Sam N, ... ... Lopez-Berestein G, et al. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports. PMID 26686630 DOI: 10.1016/J.Celrep.2015.11.047 |
0.471 |
|
| 2015 |
Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Beretta L. Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. Hepatology (Baltimore, Md.). PMID 26599259 DOI: 10.1002/Hep.28367 |
0.324 |
|
| 2015 |
Kang Y, Nagaraja AS, Armaiz-Pena GN, Dorniak PL, Hu W, Rupaimoole R, Liu T, Gharpure KM, Previs RA, Hansen JM, Rodriguez-Aguayo C, Ivan C, Ram PT, Sehgal V, Lopez-Berestein G, et al. Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26581245 DOI: 10.1158/1078-0432.Ccr-15-1275 |
0.397 |
|
| 2015 |
Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, ... ... Lopez-Berestein G, et al. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. PMID 26481148 DOI: 10.1016/J.Ccell.2015.09.008 |
0.454 |
|
| 2015 |
Park YY, Sohn BH, Johnson RL, Kang MH, Kim SB, Shim JJ, Mangala LS, Kim JH, Yoo JE, Rodriguez-Aguayo C, Pradeep S, Hwang JE, Jang HJ, Lee HS, Rupaimoole R, ... Lopez-Berestein G, et al. YAP1 and TAZ Activates mTORC1 Pathway by Regulating Amino Acid Transporters in hepatocellular carcinoma. Hepatology (Baltimore, Md.). PMID 26389641 DOI: 10.1002/Hep.28223 |
0.381 |
|
| 2015 |
Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, Blessing AM, Ivan C, Wu SY, Varkaris A, Shi Y, Lopez-Berestein G, Frigo DE, Sood AK, Gallick GE. Chitosan nanoparticle-mediated delivery of MiRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. PMID 26313360 DOI: 10.18632/Oncotarget.4971 |
0.373 |
|
| 2015 |
Nagaraja AS, Dorniak PL, Sadaoui NC, Kang Y, Lin T, Armaiz-Pena G, Wu SY, Rupaimoole R, Allen JK, Gharpure KM, Pradeep S, Zand B, Previs RA, Hansen JM, Ivan C, ... ... Lopez-Berestein G, et al. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene. PMID 26257064 DOI: 10.1038/Onc.2015.302 |
0.444 |
|
| 2015 |
Timsah Z, Ahmed Z, Ivan C, Berrout J, Gagea M, Zhou Y, Pena GN, Hu X, Vallien C, Kingsley CV, Lu Y, Hancock JF, Liu J, Gladden AB, Mills GB, ... Lopez-Berestein G, et al. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene. PMID 26212011 DOI: 10.1038/Onc.2015.279 |
0.428 |
|
| 2015 |
Gharpure KM, Wu SY, Li C, Lopez-Berestein G, Sood AK. Nanotechnology: Future of Oncotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3121-30. PMID 26180057 DOI: 10.1158/1078-0432.Ccr-14-1189 |
0.356 |
|
| 2015 |
Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, Jennings N, Rodriguez-Aguayo C, Lopez-Berestein G, Miranda R, Qiao W, Baladandayuthapani V, Li Z, Sood AK, Liu J, et al. CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. Plos One. 10: e0131833. PMID 26146988 DOI: 10.1371/Journal.Pone.0131833 |
0.477 |
|
| 2015 |
Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, ... ... Lopez-Berestein G, et al. The ZNF304-integrin axis protects against anoikis in cancer. Nature Communications. 6: 7351. PMID 26081979 DOI: 10.1038/Ncomms8351 |
0.451 |
|
| 2015 |
Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, et al. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. Journal of the National Cancer Institute. 107. PMID 25995442 DOI: 10.1093/Jnci/Djv108 |
0.391 |
|
| 2015 |
Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, et al. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 520: 697-701. PMID 25901683 DOI: 10.1038/Nature14418 |
0.444 |
|
| 2015 |
Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Jennings NB, Dorniak P, Hansen JM, Arevalo JM, Cole SW, Lutgendorf SK, ... ... Lopez-Berestein G, et al. Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget. 6: 4266-73. PMID 25738355 DOI: 10.18632/Oncotarget.2887 |
0.374 |
|
| 2015 |
Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot C, et al. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene. PMID 25639871 DOI: 10.1038/Onc.2014.469 |
0.396 |
|
| 2015 |
Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriguez-Aguayo C, Fernandez-de Thomas RJ, Aslan B, Del C Monroig P, Velazquez-Torres G, Previs RA, Pradeep S, Kahraman N, Wang H, Kanlikilicer P, Ozpolat B, ... ... Lopez-Berestein G, et al. Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2127-37. PMID 25595279 DOI: 10.1158/1078-0432.Ccr-14-2279 |
0.392 |
|
| 2015 |
Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang W. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. The Journal of Pathology. 235: 25-36. PMID 25230372 DOI: 10.1002/Path.4443 |
0.344 |
|
| 2015 |
Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang T, Xie X, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan Y. Abstract P6-17-01: MicroRNA-34a suppresses breast cancer bone metastasis by inhibiting osteoclastogenesis and targeting tgif2 Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-17-01 |
0.336 |
|
| 2015 |
Wu SY, Filant J, McGuire M, Rupaimoole R, Pradeep S, Unruh A, Shelley H, Ivan C, Dennis R, Rodriguez-Aguayo C, Sehgal V, Miyake T, Nagaraja A, Gharpure K, Armaiz G, ... ... Lopez-Berestein G, et al. Abstract 5466: Integrative TCGA analyses identify Basonuclin1 (BNC1) as a key mediator for platinum resistance Cancer Research. 75: 5466-5466. DOI: 10.1158/1538-7445.Am2015-5466 |
0.467 |
|
| 2015 |
Napoli M, Venkatanarayan A, Raulji P, Abbas HA, Norton W, Sood AK, Lopez-Berestein G, Tsai KY, Coarfa C, Gunaratne PH, Flores ER. Abstract 3975: Pharmacologic inhibition of the ΔNp63/DGCR8 axis as a novel therapeutic strategy for p53-deficient and mutant tumors Cancer Research. 75: 3975-3975. DOI: 10.1158/1538-7445.Am2015-3975 |
0.403 |
|
| 2015 |
Ashour A, Erdogan A, Alpay SN, Kahraman N, Yuka E, Lopez-Berestein G, Ozpolat B. Abstract 2642: EF2-kinase (EF2K): A novel molecular target in ovarian and pancreatic cancers Cancer Research. 75: 2642-2642. DOI: 10.1158/1538-7445.Am2015-2642 |
0.491 |
|
| 2015 |
Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Dorniak P, Previs R, Sadaoui N, Stone R, Matsuo K, Dalton HJ, Lutgendorf SK, Sood AK, Lopez-Berestein G. Abstract 2359: Adrenergic regulation of MCP-1 leads to enhanced macrophage recruitment and ovarian carcinoma growth Cancer Research. 75: 2359-2359. DOI: 10.1158/1538-7445.Am2015-2359 |
0.403 |
|
| 2015 |
Gharpure KM, Tucker SL, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, et al. Abstract 2273: Mechanistic and functional implications of FABP4 in ovarian cancer metastasis Cancer Research. 75: 2273-2273. DOI: 10.1158/1538-7445.Am2015-2273 |
0.448 |
|
| 2015 |
Pradeep S, Huang J, Mora E, Nick A, Cho M, Wu S, Rupaimoole R, Xiong C, Li C, Lopez-Berestein G, Jackson D, Sood A. Abstract 1952: Adverse effects of erythropoietin stimulates tumor growth via EphB4 Cancer Research. 75: 1952-1952. DOI: 10.1158/1538-7445.Am2015-1952 |
0.436 |
|
| 2015 |
Rupaimole R, Previs R, Lee J, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison J, Rodriguez-Aguayo C, Calin GA, Mills G, Zhang W, Lopez-Berestein G, Bhattacharya P, Sood AK. Abstract 142: SiRNA therapy against novel lncRNA NRCP: shutting down the fuel for cancer cells Cancer Research. 75: 142-142. DOI: 10.1158/1538-7445.Am2015-142 |
0.384 |
|
| 2015 |
Zand B, Previs R, Zacharias N, Rupaimoole R, Dalton H, Hansen J, Rodriguez-Aguayo C, Guindani M, Lopez-Berestein G, Bhattacharya P, Sood A. Role of increased n-acetylaspartate levels in epithelial ovarian cancer Gynecologic Oncology. 137: 68. DOI: 10.1016/J.Ygyno.2015.01.161 |
0.365 |
|
| 2014 |
Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, ... ... Lopez-Berestein G, et al. Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell. 26: 863-79. PMID 25490449 DOI: 10.1016/J.Ccell.2014.10.010 |
0.349 |
|
| 2014 |
Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, Woodward WA, Liang H, Yang X, Lopez-Berestein G, Sood AK, et al. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nature Communications. 5: 5671. PMID 25476932 DOI: 10.1038/Ncomms6671 |
0.358 |
|
| 2014 |
Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, ... ... Lopez-Berestein G, et al. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nature Communications. 5: 5202. PMID 25351346 DOI: 10.1038/Ncomms6202 |
0.31 |
|
| 2014 |
Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, ... ... Lopez-Berestein G, et al. Therapeutic silencing of KRAS using systemically delivered siRNAs. Molecular Cancer Therapeutics. 13: 2876-85. PMID 25281617 DOI: 10.1158/1535-7163.Mct-14-0074 |
0.454 |
|
| 2014 |
Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nature Communications. 5: 5092. PMID 25277212 DOI: 10.1038/Ncomms6092 |
0.442 |
|
| 2014 |
Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E, Deng D, Hwang RF, Wang H, Ivan C, Garza RJ, Cohen E, Gao H, Armaiz-Pena GN, Del C Monroig-Bosque P, Philip B, ... ... Lopez-Berestein G, et al. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. Molecular Cancer Therapeutics. 13: 2583-94. PMID 25193509 DOI: 10.1158/1535-7163.Mct-14-0028 |
0.399 |
|
| 2014 |
Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, ... ... Lopez-Berestein G, et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 26: 77-91. PMID 25026212 DOI: 10.1016/J.Ccr.2014.05.002 |
0.437 |
|
| 2014 |
Wu SY, Lopez-Berestein G, Calin GA, Sood AK. RNAi therapies: drugging the undruggable. Science Translational Medicine. 6: 240ps7. PMID 24920658 DOI: 10.1126/Scitranslmed.3008362 |
0.348 |
|
| 2014 |
Reusser NM, Dalton HJ, Pradeep S, Gonzalez-Villasana V, Jennings NB, Vasquez HG, Wen Y, Rupaimoole R, Nagaraja AS, Gharpure K, Miyake T, Huang J, Hu W, Lopez-Berestein G, Sood AK. Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biology & Therapy. 15: 1061-7. PMID 24841852 DOI: 10.4161/Cbt.29184 |
0.315 |
|
| 2014 |
Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Molecular Systems Biology. 10: 728. PMID 24799285 DOI: 10.1002/Msb.20134892 |
0.373 |
|
| 2014 |
Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, et al. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3280-8. PMID 24756370 DOI: 10.1158/1078-0432.Ccr-14-0445 |
0.317 |
|
| 2014 |
Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, et al. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biology & Therapy. 15: 919-29. PMID 24755674 DOI: 10.4161/Cbt.28882 |
0.409 |
|
| 2014 |
Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY, Luft JC, Napier ME, Lopez-Berestein G, DeSimone JM, et al. Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Molecular Cancer Therapeutics. 13: 1750-7. PMID 24755199 DOI: 10.1158/1535-7163.Mct-13-0930 |
0.402 |
|
| 2014 |
Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, ... ... Lopez-Berestein G, et al. Notch3 pathway alterations in ovarian cancer. Cancer Research. 74: 3282-93. PMID 24743243 DOI: 10.1158/0008-5472.Can-13-2066 |
0.431 |
|
| 2014 |
Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, ... ... Lopez-Berestein G, et al. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Reports. 7: 488-500. PMID 24703838 DOI: 10.1016/J.Celrep.2014.03.009 |
0.442 |
|
| 2014 |
Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, ... ... Lopez-Berestein G, et al. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications. 5: 3459. PMID 24619206 DOI: 10.1038/Ncomms4459 |
0.388 |
|
| 2014 |
Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, ... Lopez-Berestein G, et al. Autocrine effects of tumor-derived complement. Cell Reports. 6: 1085-95. PMID 24613353 DOI: 10.1016/J.Celrep.2014.02.014 |
0.451 |
|
| 2014 |
Dalton HJ, Armaiz-Pena GN, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli M, Sood AK. Monocyte subpopulations in angiogenesis. Cancer Research. 74: 1287-93. PMID 24556724 DOI: 10.1158/0008-5472.Can-13-2825 |
0.371 |
|
| 2014 |
Zhaorigetu S, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G, Walton BL. Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. Journal of Liposome Research. 24: 182-90. PMID 24443972 DOI: 10.3109/08982104.2013.863208 |
0.327 |
|
| 2014 |
Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Advanced Drug Delivery Reviews. 66: 110-6. PMID 24384374 DOI: 10.1016/J.Addr.2013.12.008 |
0.306 |
|
| 2014 |
Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Landen CN, Eblen ST. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis. 35: 1100-9. PMID 24379240 DOI: 10.1093/Carcin/Bgt489 |
0.457 |
|
| 2014 |
Pecot C, Wu S, Bellister S, Bhattacharya R, Maharaj A, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Lopez-Berestein G, Ellis LM, Sood A. Abstract B47: Therapeutic KRAS silencing in lung and colon cancer models Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-B47 |
0.445 |
|
| 2014 |
Gharpure KM, Chu KS, Bowerman C, Miyake T, Pradeep S, Mangala LS, Han H, Rupaimoole R, Wu SY, Dalton HJ, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AK. Abstract 5403: Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer Cancer Research. 74: 5403-5403. DOI: 10.1158/1538-7445.Am2014-5403 |
0.367 |
|
| 2014 |
Jiang D, Mangala LS, Wang H, Wu S, Rao LG, Rodriguez-Aguayo C, Pradeep S, Volk DE, Lopez-Berestein G, Sood AK. Abstract 4468: Tumor vasculature targeting using cell-specific thioaptamer decorated chitosan nanoparticle Cancer Research. 74: 4468-4468. DOI: 10.1158/1538-7445.Am2014-4468 |
0.403 |
|
| 2014 |
Rupaimoole R, Ivan C, Pecot C, Wu S, Pradeep S, Zand B, Nagaraja A, Gharpure K, Dalton H, Sadaoui N, Zhang W, Lopez-Berestein G, Sood A. Abstract 3532: Hypoxia is a master regulator of Drosha- and Dicer-dependent miRNA biogenesis in cancer Cancer Research. 74: 3532-3532. DOI: 10.1158/1538-7445.Am2014-3532 |
0.387 |
|
| 2014 |
Gonzalez-Villasana V, Rodriguez-Aguayo C, Fuentes-Mattei E, Pradeep S, Ivan C, Sood AK, Lopez-Berestein G. Abstract 2992: Zoledronic acid inhibits angiogenesis through Rac1 inactivation in ovarian cancer Cancer Research. 74: 2992-2992. DOI: 10.1158/1538-7445.Am2014-2992 |
0.443 |
|
| 2014 |
Dalton HJ, Reusser NM, Zien A, Jackson D, Previs R, Rupaimoole R, Zand B, Lopez-Berestein G, Coleman RL, Sood AK. Abstract 2983: Bisphosphonates: New strategies for targeting angiogenesis in ovarian cancer Cancer Research. 74: 2983-2983. DOI: 10.1158/1538-7445.Am2014-2983 |
0.463 |
|
| 2014 |
Dalton HJ, Pradeep S, Armaiz-Pena GN, Previs R, Davis A, Rupaimoole R, Zand B, Hailemichael Y, Overwijk WW, Lopez-Berestein G, Sood AK. Abstract 2982: Macrophages modulate adaptive resistance to anti-angiogenic therapy Cancer Research. 74: 2982-2982. DOI: 10.1158/1538-7445.Am2014-2982 |
0.389 |
|
| 2014 |
Armaiz-Pena GN, Nagaraja AS, Allen JK, Sadaoui NC, Rupaimoole R, wu sY, Pradeep S, Han HD, Zand B, Dalton H, Previs R, Taylor M, Bottsford-Miller J, Mangala LS, Rodriguez-Aguayo C, ... ... Lopez-Berestein G, et al. Abstract 1062: Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction Cancer Research. 74: 1062-1062. DOI: 10.1158/1538-7445.Am2014-1062 |
0.387 |
|
| 2014 |
Hu W, Liu T, Ivan C, Huang J, Dalton H, Previs R, Nick A, Lopez-Berestein G, Coleman R, Sood A. Selective activation of Notch3 in high-grade serous ovarian cancer Gynecologic Oncology. 133: 115. DOI: 10.1016/J.Ygyno.2014.03.304 |
0.372 |
|
| 2013 |
Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, Mukherjee P. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. Plos One. 8: e79167. PMID 24236104 DOI: 10.1371/Journal.Pone.0079167 |
0.451 |
|
| 2013 |
Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G. Nanotechnology in cancer therapy. Journal of Drug Targeting. 21: 904-13. PMID 24079419 DOI: 10.3109/1061186X.2013.837469 |
0.391 |
|
| 2013 |
Tekedereli I, Alpay SN, Akar U, Yuca E, Ayugo-Rodriguez C, Han HD, Sood AK, Lopez-Berestein G, Ozpolat B. Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer. Molecular Therapy. Nucleic Acids. 2: e121. PMID 24022053 DOI: 10.1038/Mtna.2013.45 |
0.447 |
|
| 2013 |
Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, ... ... Lopez-Berestein G, et al. Tumour angiogenesis regulation by the miR-200 family. Nature Communications. 4: 2427. PMID 24018975 DOI: 10.1038/Ncomms3427 |
0.36 |
|
| 2013 |
Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, ... ... Lopez-Berestein G, et al. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discovery. 3: 1302-15. PMID 24002999 DOI: 10.1158/2159-8290.Cd-13-0159 |
0.404 |
|
| 2013 |
Masiero M, Simões FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, et al. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 24: 229-41. PMID 23871637 DOI: 10.1016/J.Ccr.2013.06.004 |
0.397 |
|
| 2013 |
Jin Y, Qu S, Tesikova M, Wang L, Kristian A, Mælandsmo GM, Kong H, Zhang T, Jerónimo C, Teixeira MR, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood AK, ... Lopez-Berestein G, et al. Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 110: E2572-81. PMID 23798432 DOI: 10.1073/Pnas.1304318110 |
0.393 |
|
| 2013 |
Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, ... ... Lopez-Berestein G, et al. ATP11B mediates platinum resistance in ovarian cancer. The Journal of Clinical Investigation. 123: 2119-30. PMID 23585472 DOI: 10.1172/JCI65425 |
0.34 |
|
| 2013 |
Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 23: 186-99. PMID 23410973 DOI: 10.1016/J.Ccr.2012.12.020 |
0.348 |
|
| 2013 |
Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, Lu Y, Rodriguez-Aguayo C, Lopez-Berestein G, Mills GB, Sood AK, Lee JS. Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology (Baltimore, Md.). 58: 182-91. PMID 23389994 DOI: 10.1002/Hep.26310 |
0.385 |
|
| 2013 |
Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, ... ... Lopez-Berestein G, et al. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1806-15. PMID 23386691 DOI: 10.1158/1078-0432.Ccr-12-2764 |
0.425 |
|
| 2013 |
Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, ... ... Lopez-Berestein G, et al. Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nature Communications. 4: 1403. PMID 23360994 DOI: 10.1038/Ncomms2413 |
0.394 |
|
| 2013 |
Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 809-20. PMID 23344261 DOI: 10.1158/1078-0432.Ccr-12-2736 |
0.42 |
|
| 2013 |
Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecologic Oncology. 128: 506-11. PMID 23200915 DOI: 10.1016/J.Ygyno.2012.11.029 |
0.391 |
|
| 2013 |
Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 170-82. PMID 23147994 DOI: 10.1158/1078-0432.Ccr-12-1045 |
0.478 |
|
| 2013 |
Shahzad MM, Shin YH, Matsuo K, Lu C, Nishimura M, Shen DY, Kang Y, Hu W, Mora EM, Rodriguez-Aguayo C, Kapur A, Bottsford-Miller J, Lopez-Berestein G, Rajkovic A, Sood AK. Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Letters. 330: 123-9. PMID 22776561 DOI: 10.1016/J.Canlet.2012.07.001 |
0.451 |
|
| 2013 |
Moreno-Smith M, Halder J, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, ... ... Lopez-Berestein G, et al. ATP11B mediates platinum resistance in ovarian cancer Journal of Clinical Investigation. 123: 5411-5411. DOI: 10.1172/Jci73904 |
0.379 |
|
| 2013 |
Zhang S, Mao W, Sood AK, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Li Z, Bast RC, Le X. Abstract 5433: Knockdown of the glycolytic enzyme PFKFB2 induces growth inhibition and enhances paclitaxel sensitivity in ovarian cancer cells. Cancer Research. 73: 5433-5433. DOI: 10.1158/1538-7445.Am2013-5433 |
0.463 |
|
| 2013 |
Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Deng D, Fuentes-Mattei E, Hwang RF, Wang H, Pena GNA, Aslan B, Gutierrez-Puente Y, Sood AK, Logsdon C, Lopez-Berestein G. Abstract 4959: Targeting pancreatic stellate cells (PSC) to treat pancreatic cancer. Cancer Research. 73: 4959-4959. DOI: 10.1158/1538-7445.Am2013-4959 |
0.456 |
|
| 2013 |
Rodriguez-Aguayo C, Shen H, Gonzalez-Villasana V, Zhang G, Deng X, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han H, Sood AK, Ferrari M, Lopez-Berestein G. Abstract 3269: Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery . Cancer Research. 73: 3269-3269. DOI: 10.1158/1538-7445.Am2013-3269 |
0.435 |
|
| 2013 |
Wu SY, Unruh AK, Rupaimoole R, Ivan C, Ruder D, Pradeep S, Sehgal V, Rodriguez-Aguayo C, Pecot C, Miyake T, Lopez-Berestein G, Ram P, Baggerly KA, Sood AK. Abstract 2036: Overcoming platinum-resistance in ovarian cancer via targeting basonuclin1 (BNC1). Cancer Research. 73: 2036-2036. DOI: 10.1158/1538-7445.Am2013-2036 |
0.456 |
|
| 2013 |
Hu W, Ivan C, Bottsford-Miller J, Zand B, Dalton H, Nick A, Lopez-Berestein G, Coleman R, Bagglerly K, Sood A. Comprehensive epigenetic analysis of Notch pathway in high-grade serous ovarian cancer Gynecologic Oncology. 130: e115. DOI: 10.1016/J.Ygyno.2013.04.333 |
0.39 |
|
| 2013 |
Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, et al. Integrated analyses identify a master microrna regulatory network for the mesenchymal subtype in serous ovarian cancer [Cancer Cell 23 (2013) 186-199] Cancer Cell. 23. DOI: 10.1016/J.Ccr.2013.04.029 |
0.411 |
|
| 2012 |
Shao L, Tekedereli I, Wang J, Yuca E, Tsang S, Sood A, Lopez-Berestein G, Ozpolat B, Ittmann M. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6648-57. PMID 23052253 DOI: 10.1158/1078-0432.Ccr-12-2715 |
0.374 |
|
| 2012 |
Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN, Ozpolat B. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. Plos One. 7: e41171. PMID 22911754 DOI: 10.1371/Journal.Pone.0041171 |
0.452 |
|
| 2012 |
Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Research : Bcr. 14: R108. PMID 22812534 DOI: 10.1186/Bcr3229 |
0.368 |
|
| 2012 |
Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. 33: 1843-53. PMID 22581827 DOI: 10.1093/Carcin/Bgs167 |
0.426 |
|
| 2012 |
Hussein YR, Sood AK, Bandyopadhyay S, Albashiti B, Semaan A, Nahleh Z, Roh J, Han HD, Lopez-Berestein G, Ali-Fehmi R. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Human Pathology. 43: 1638-44. PMID 22436627 DOI: 10.1016/J.Humpath.2011.12.004 |
0.404 |
|
| 2012 |
Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, ... ... Lopez-Berestein G, et al. Paraneoplastic thrombocytosis in ovarian cancer. The New England Journal of Medicine. 366: 610-8. PMID 22335738 DOI: 10.1056/Nejmoa1110352 |
0.404 |
|
| 2012 |
Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK. Erratum to: Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer Breast Cancer Research. 14. DOI: 10.1186/Bcr3370 |
0.344 |
|
| 2012 |
Wu SY, Unruh AK, Bartholomeusz G, Ivan C, Pecot CV, Rupaimoole R, Han H, Bottsford-Miller J, Tucker SL, Coleman RL, Lopez-Berestein G, Baggerly KA, Sood AK. Abstract 884: Basonuclin1 (BNC1): A novel therapeutic target in ovarian cancer identified through integrative TCGA-based functional genomic analysis Cancer Research. 72: 884-884. DOI: 10.1158/1538-7445.Am2012-884 |
0.439 |
|
| 2012 |
Vathipadiekal V, Ozbun L, Lee J, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Mok SC, Birrer MJ. Abstract 5057: Gene expression profile of chemoresponse of microdissected papillary serous tumors of the ovary identifies POLH and REV3L as potential therapeutic targets Cancer Research. 72: 5057-5057. DOI: 10.1158/1538-7445.Am2012-5057 |
0.461 |
|
| 2012 |
Park Y, Jung SY, Rodriguez-Aguayo C, Peng G, Lee S, Kim SB, Kim K, Leem S, Lin S, Lopez-Berestein G, Sood AK, Lee J. Abstract 2962: FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair Cancer Research. 72: 2962-2962. DOI: 10.1158/1538-7445.Am2012-2962 |
0.431 |
|
| 2011 |
Samuel S, Gaur P, Fan F, Xia L, Gray MJ, Dallas NA, Bose D, Rodriguez-Aguayo C, Lopez-Berestein G, Plowman G, Bagri A, Sood AK, Ellis LM. Neuropilin-2 mediated β-catenin signaling and survival in human gastro-intestinal cancer cell lines. Plos One. 6: e23208. PMID 22028766 DOI: 10.1371/Journal.Pone.0023208 |
0.481 |
|
| 2011 |
Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, ... ... Lopez-Berestein G, et al. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. Journal of the National Cancer Institute. 103: 1596-612. PMID 21957230 DOI: 10.1093/Jnci/Djr372 |
0.314 |
|
| 2011 |
Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P, Rashid A, Fleming JB, Abdalla EK, Curley SA, Vauthey JN, et al. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 141: 1728-37. PMID 21806944 DOI: 10.1053/J.Gastro.2011.07.037 |
0.416 |
|
| 2011 |
Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, ... ... Lopez-Berestein G, et al. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Research. 71: 6030-9. PMID 21795478 DOI: 10.1158/0008-5472.Can-10-2719 |
0.326 |
|
| 2011 |
Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, ... ... Lopez-Berestein G, et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. Plos One. 6: e21121. PMID 21754983 DOI: 10.1371/Journal.Pone.0021121 |
0.479 |
|
| 2011 |
Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CN. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5674-85. PMID 21753153 DOI: 10.1158/1078-0432.Ccr-11-0432 |
0.386 |
|
| 2011 |
Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3716-26. PMID 21512144 DOI: 10.1158/1078-0432.Ccr-11-0233 |
0.387 |
|
| 2011 |
Wang E, Bhattacharyya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P, Sood AK, Bhattacharya R. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. Plos One. 6: e17918. PMID 21445297 DOI: 10.1371/Journal.Pone.0017918 |
0.466 |
|
| 2011 |
Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RK. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2250-9. PMID 21421858 DOI: 10.1158/1078-0432.Ccr-10-2718 |
0.441 |
|
| 2011 |
Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, et al. Functional roles of Src and Fgr in ovarian carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1713-21. PMID 21300758 DOI: 10.1158/1078-0432.Ccr-10-2081 |
0.456 |
|
| 2011 |
Pena GNA, Stone RL, Nick AM, Villares GJ, Cruz A, Vivas-Mejias P, Wu Z, English RD, Soman KV, Deavers MT, Zien A, Soldatos T, Jackson DB, Wiktorowicz JE, Torres-Lugo M, ... ... Lopez-Berestein G, et al. Abstract 937: Molecular dynamics of SrcS17 activation in chronic stress-induced tumor growth Cancer Research. 71: 937-937. DOI: 10.1158/1538-7445.Am2011-937 |
0.419 |
|
| 2011 |
Alpay N, Tekedereli I, Lopez-Berestein G, Dalby K, Ozpolat B. Abstract 3787: Serotonin signaling plays a role in regulation of autophagy in breast cancer cells Cancer Research. 71: 3787-3787. DOI: 10.1158/1538-7445.Am2011-3787 |
0.427 |
|
| 2011 |
Rodriguez-Aguayo C, Vivas-Mejia PE, Han H, Shahzad MMK, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Abstract 1735: Silencing survivin splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer Cancer Research. 71: 1735-1735. DOI: 10.1158/1538-7445.Am2011-1735 |
0.444 |
|
| 2011 |
Bradley AT, Zheng H, Ziebarth A, Sakati W, Eier S, Lopez-Berestein G, Sood AK, Landen C, Eblen ST. Abstract 1649: The E3 ubiquitin ligase EDD regulates platinum resistance and is a novel therapeutic target for epithelial ovarian cancer Cancer Research. 71: 1649-1649. DOI: 10.1158/1538-7445.Am2011-1649 |
0.469 |
|
| 2011 |
Mora EM, Pecot CV, Nick AM, Mangala LS, Han HD, Stein MA, Brock S, Vivas-Mejias P, Sung B, Nishimura M, Matsuo K, Kannan S, Zweidler-McKay PA, Armaiz-Pena GN, Shahzad MMK, ... ... Lopez-Berestein G, et al. Abstract 1618: Erythropoietin meets a new receptor Cancer Research. 71: 1618-1618. DOI: 10.1158/1538-7445.Am2011-1618 |
0.435 |
|
| 2011 |
Gonzalez-Villasana V, Nieves-Alicea R, McMurtry V, Huaringa A, Simeone A, Gutierrez-Puente Y, Lopez-Berestein G, Tari AM. Abstract 1426: Cyclooxygenase-2 (COX-2) utilizes Jun N-terminal kinases to induce invasion but not tamoxifen resistance in MCF-7 breast cancer cells Cancer Research. 71: 1426-1426. DOI: 10.1158/1538-7445.Am2011-1426 |
0.442 |
|
| 2011 |
Ziebarth A, Zheng H, Bradley A, Sakati W, Eier S, Lopez-Berestein G, Sood A, Eblen S, Landen C. The ubiquitin ligase EDD mediates platinum resistance and is a target for therapy in epithelial ovarian cancer Gynecologic Oncology. 120: S26-S27. DOI: 10.1016/J.Ygyno.2010.12.066 |
0.392 |
|
| 2010 |
Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Molecular Cancer Therapeutics. 9: 3186-99. PMID 20889728 DOI: 10.1158/1535-7163.Mct-10-0563 |
0.468 |
|
| 2010 |
Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Kaftanovskaya EM, Pereira R, Han HD, Lopez-Berestein G, Klonisch T, Ittmann MM, Sood AK, Agoulnik AI. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocrine-Related Cancer. 17: 1021-33. PMID 20861284 DOI: 10.1677/Erc-10-0073 |
0.442 |
|
| 2010 |
Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, et al. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. The Journal of Biological Chemistry. 285: 35462-70. PMID 20826776 DOI: 10.1074/Jbc.M110.109579 |
0.329 |
|
| 2010 |
Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, et al. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell. 18: 109-21. PMID 20708153 DOI: 10.1016/J.Ccr.2010.06.018 |
0.424 |
|
| 2010 |
Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN, Arun B. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Molecular Cancer Therapeutics. 9: 1180-7. PMID 20423989 DOI: 10.1158/1535-7163.Mct-09-1025 |
0.453 |
|
| 2010 |
Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, ... ... Lopez-Berestein G, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. The Journal of Clinical Investigation. 120: 1515-23. PMID 20389021 DOI: 10.1172/Jci40802 |
0.45 |
|
| 2010 |
Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy. 6: 322-9. PMID 20224296 DOI: 10.4161/Auto.6.3.11625 |
0.452 |
|
| 2010 |
Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, ... ... Lopez-Berestein G, et al. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 184-94. PMID 20028751 DOI: 10.1158/1078-0432.Ccr-09-1180 |
0.478 |
|
| 2010 |
Tanaka T, Lingegowda M, Nieves-Alicea R, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Ferrari M. Abstract LB-143: Sustained siRNA delivery by mesoporous silicon particles Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-143 |
0.416 |
|
| 2010 |
Tekedereli I, Lopez-Berestein G, Ozpolat B. Abstract 88: Targeting Bcl-XL enhances arsenic-induced cell death in ovarian cancer cells Cancer Research. 70: 88-88. DOI: 10.1158/1538-7445.Am10-88 |
0.445 |
|
| 2010 |
Vivas PE, Rodríguez-Aguayo C, Han H, Shahzad MM, Sood AK, Lopez-Berestein G. Abstract 677: Targeting the survivin splice variant 2β in taxane-resistant ovarian cancer Cancer Research. 70: 677-677. DOI: 10.1158/1538-7445.Am10-677 |
0.441 |
|
| 2010 |
Shahzad MM, Mangala LS, Lee JW, Matsuo K, Nair MP, Han HD, Mora EM, Lu C, Gaur P, Haghpeykar SB, Carroll AR, Stone RL, Lopez-Berestein G, Lacko AG, Sood AK. Abstract 5517: Targeting anticancer therapeutics: A role for reconstituted high density lipoprotein (rHDL) Cancer Research. 70: 5517-5517. DOI: 10.1158/1538-7445.Am10-5517 |
0.437 |
|
| 2010 |
Rodriguez-Aguayo C, Vivas-Mejia P, Benito JM, Fernandez A, Francois-Xavier C, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Abstract 5468: JNK-1 inhibition leads to antitumor activity in ovarian cancer Cancer Research. 70: 5468-5468. DOI: 10.1158/1538-7445.Am10-5468 |
0.497 |
|
| 2010 |
Ozpolat B, Tekedereli I, Akar U, Lopez-Berestein G. Abstract 5108: Silencing of Bcl-2 by liposomal siRNA enhances Doxorubicin-induced autophagy and inhibits in vivo tumor growth of ER(−) and ER(−) breast cancers Cancer Research. 70: 5108-5108. DOI: 10.1158/1538-7445.Am10-5108 |
0.455 |
|
| 2010 |
Landen CN, Goodman B, Nick AM, Stone RL, Meijia PV, Miller LD, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Abstract 4288: Targeted therapy against aldehyde dehydrogenase in ovarian cancer Cancer Research. 70: 4288-4288. DOI: 10.1158/1538-7445.Am10-4288 |
0.496 |
|
| 2010 |
Chakravarty D, Challa R, Dandamudi R, Vivas-Mejia P, Lopez-Berestein G, Tekmal RR, Sood AK, Vadlamudi RK. Abstract 3669: PELP1: A novel therapeutic target for ovarian cancer progression and metastasis Cancer Research. 70: 3669-3669. DOI: 10.1158/1538-7445.Am10-3669 |
0.502 |
|
| 2010 |
Carroll A, Kim SW, Nick AM, Stone RL, Spannuth WA, Armaiz-Pena GN, Matsuo K, Vivas-Mejia PE, Mangala S, Mora EM, Shahzad M, Lopez-Berestein G, Sood AK. Abstract 1811: Breaking scaffolds: Targeting paxillin in ovarian cancer Cancer Research. 70: 1811-1811. DOI: 10.1158/1538-7445.Am10-1811 |
0.503 |
|
| 2010 |
Nick AM, Stone RL, Spannuth WA, Landen CN, Villares G, Armaiz-Pena G, Carroll AR, Ozpolat B, Tekedereli I, Vivas-Mejia P, Coleman RL, Lopez-Berestein G, Sood AK. Abstract 1044: Silencing p130cas in ovarian carcinoma induces autophagic cell death Cancer Research. 70: 1044-1044. DOI: 10.1158/1538-7445.Am10-1044 |
0.459 |
|
| 2009 |
Ramachandran V, Arumugam T, Langley R, Hwang RF, Vivas-Mejia P, Sood AK, Lopez-Berestein G, Logsdon CD. The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment. Plos One. 4: e7502. PMID 19847298 DOI: 10.1371/Journal.Pone.0007502 |
0.45 |
|
| 2009 |
Shahzad MM, Lopez-Berestein G, Sood AK. Novel strategies for reversing platinum resistance. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 12: 148-52. PMID 19805003 DOI: 10.1016/J.Drup.2009.09.001 |
0.395 |
|
| 2009 |
Mangala LS, Han HD, Lopez-Berestein G, Sood AK. Liposomal siRNA for ovarian cancer. Methods of Molecular Biology. 555: 29-42. PMID 19495686 DOI: 10.1007/978-1-60327-295-7_3 |
0.376 |
|
| 2009 |
Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, ... ... Lopez-Berestein G, et al. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3770-80. PMID 19470734 DOI: 10.1158/1078-0432.Ccr-08-2306 |
0.32 |
|
| 2009 |
Vivas-Mejía PE, Ozpolat B, Chen X, Lopez-Berestein G. Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. International Journal of Cancer. 125: 264-75. PMID 19408305 DOI: 10.1002/Ijc.24341 |
0.322 |
|
| 2009 |
Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, et al. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biology & Therapy. 8: 1027-34. PMID 19395869 DOI: 10.4161/Cbt.8.11.8523 |
0.405 |
|
| 2009 |
Armaiz-Pena G, Villares G, Han L, Lin Y, Sanguino A, Deavers M, Gallick G, Bar-Eli M, Lopez-Berestein G, Cole S, Lutgendorf S, Sood A. 5. Molecular mechanisms of Src activation in chronic stress-induced cancer growth Brain, Behavior, and Immunity. 23: S26. DOI: 10.1016/J.Bbi.2009.06.010 |
0.343 |
|
| 2008 |
Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, ... ... Lopez-Berestein G, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. The New England Journal of Medicine. 359: 2641-50. PMID 19092150 DOI: 10.1056/Nejmoa0803785 |
0.376 |
|
| 2008 |
Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ, Logsdon CD. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 8143-51. PMID 19088029 DOI: 10.1158/1078-0432.Ccr-08-1539 |
0.433 |
|
| 2008 |
Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, Leslie MC, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Bar-Eli M. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Research. 68: 9078-86. PMID 18974154 DOI: 10.1158/0008-5472.Can-08-2397 |
0.392 |
|
| 2008 |
Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LM. Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene. 27: 7192-200. PMID 18806828 DOI: 10.1038/Onc.2008.356 |
0.447 |
|
| 2008 |
Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Research. 68: 5849-58. PMID 18632639 DOI: 10.1158/0008-5472.Can-07-6130 |
0.471 |
|
| 2008 |
Yang L, Hamilton SR, Sood A, Kuwai T, Ellis L, Sanguino A, Lopez-Berestein G, Boyd DD. The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression. Cancer Research. 68: 4321-30. PMID 18519692 DOI: 10.1158/0008-5472.Can-08-0407 |
0.446 |
|
| 2008 |
Ozpolat B, Akar U, Zorrilla-Calancha I, Vivas-Mejia P, Acevedo-Alvarez M, Lopez-Berestein G. Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Apoptosis : An International Journal On Programmed Cell Death. 13: 915-28. PMID 18491231 DOI: 10.1007/S10495-008-0222-9 |
0.343 |
|
| 2008 |
Akar U, Chaves-Reyez A, Barria M, Tari A, Sanguino A, Kondo Y, Kondo S, Arun B, Lopez-Berestein G, Ozpolat B. Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy. 4: 669-79. PMID 18424910 DOI: 10.4161/Auto.6083 |
0.413 |
|
| 2008 |
Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G, Sood AK, Aggarwal BB, Krishnan S, Gelovani JG, Mehta K. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2476-83. PMID 18413840 DOI: 10.1158/1078-0432.Ccr-07-4529 |
0.386 |
|
| 2008 |
Sood AK, Sanguino A, Lopez-Berestein G. Strategies for in vivo siRNA delivery in cancer Mini-Reviews in Medicinal Chemistry. 8: 248-255. PMID 18336345 DOI: 10.2174/138955708783744074 |
0.375 |
|
| 2008 |
Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. Journal of the National Cancer Institute. 100: 359-72. PMID 18314475 DOI: 10.1093/Jnci/Djn024 |
0.355 |
|
| 2008 |
Gray MJ, Van Buren G, Dallas NA, Xia L, Wang X, Yang AD, Somcio RJ, Lin YG, Lim S, Fan F, Mangala LS, Arumugam T, Logsdon CD, Lopez-Berestein G, Sood AK, et al. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. Journal of the National Cancer Institute. 100: 109-20. PMID 18182619 DOI: 10.1093/Jnci/Djm279 |
0.449 |
|
| 2008 |
Fernandez A, Sanguino A, Peng Z, Crespo A, Ozturk E, Zhang X, Wang S, Bornmann W, Lopez-Berestein G. Rational Drug Redesign to Overcome Drug Resistance in Cancer Therapy: Imatinib Moving Target Aacr Education Book. 2008: 589-599. DOI: 10.1158/Aacr.Edb-Can-07-0345 |
0.336 |
|
| 2008 |
Armaiz-Pena GN, Mangala LS, Han LY, Lin YG, Schmandt R, Sanguino AM, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. 34. Chronic stress promotes tumor growth through a Src-dependent mechanism in a mouse model of ovarian cancer Brain Behavior and Immunity. 22: 9-10. DOI: 10.1016/J.Bbi.2008.04.035 |
0.388 |
|
| 2007 |
Fernández A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, ... ... Lopez-Berestein G, et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. The Journal of Clinical Investigation. 117: 4044-54. PMID 18060038 DOI: 10.1172/Jci32373 |
0.323 |
|
| 2007 |
Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Tae JK, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma Cancer Research. 67: 10976-10983. PMID 18006843 DOI: 10.1158/0008-5472.Can-07-2667 |
0.451 |
|
| 2007 |
Landen CN, Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, Kamat AA, Han LY, Jennings NB, Spannuth WA, Thaker PH, Lutgendorf SK, Savary CA, Sanguino AM, Lopez-Berestein G, Cole SW, et al. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Research. 67: 10389-96. PMID 17974982 DOI: 10.1158/0008-5472.Can-07-0858 |
0.362 |
|
| 2007 |
Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Jennings N, Arevalo J, Lutgendorf SK, Gallick GE, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK. Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism Journal of Biological Chemistry. 282: 29919-29926. PMID 17716980 DOI: 10.1074/Jbc.M611539200 |
0.354 |
|
| 2007 |
Ozpolat B, Akar U, Mehta K, Lopez-Berestein G. PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells. Autophagy. 3: 480-3. PMID 17507797 DOI: 10.4161/Auto.4349 |
0.447 |
|
| 2007 |
Cheema SK, Gobin AS, Rhea R, Lopez-Berestein G, Newman RA, Mathur AB. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells. International Journal of Pharmaceutics. 341: 221-9. PMID 17499461 DOI: 10.1016/J.Ijpharm.2007.03.043 |
0.779 |
|
| 2007 |
Fernández A, Sanguino A, Peng Z, Crespo A, Ozturk E, Zhang X, Wang S, Bornmann W, Lopez-Berestein G. Rational drug redesign to overcome drug resistance in cancer therapy: Imatinib moving target Cancer Research. 67: 4028-4033. PMID 17483313 DOI: 10.1158/0008-5472.Can-07-0345 |
0.336 |
|
| 2007 |
Akar U, Ozpolat B, Mehta K, Fok J, Kondo Y, Lopez-Berestein G. Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Molecular Cancer Research : McR. 5: 241-9. PMID 17374730 DOI: 10.1158/1541-7786.Mcr-06-0229 |
0.44 |
|
| 2007 |
Ozpolat B, Akar U, Zorilla-Calancha I, Vivas-Mejia P, Lopez-Berestein G. Death Associated Protein 5 (DAP5/p97/NAT1) Contributes to Retinoic Acid-Induced Granulocytic Differentiation and Arsenic Trioxide Induced Apotosis through Inhibition of PI3K/Akt/mTOR Pathway in Acute Promyelocytic Leukemia Cells: A Novel Mechanism. Blood. 110: 2836-2836. DOI: 10.1182/Blood.V110.11.2836.2836 |
0.365 |
|
| 2007 |
Ozpolat B, Akar U, Colburn NH, Lopez-Berestein G. Novel Tumor Suppressor Protein Programmed Cell Death 4 (PDCD4) Suppresses Activity of PI3K/Akt Pathway and Regulates Expression of p27 (Kip1) and c-myc, DAP5 and Willm’s Tumor (WT1) in Acute Myeloid Leukemia. Blood. 110: 2656-2656. DOI: 10.1182/Blood.V110.11.2656.2656 |
0.414 |
|
| 2007 |
Ozpolat B, Akar U, Barria M, Lopez-Berestein G. PKCδ Regulates Retinoic Acid-Induced Myeloid Cell Differentiation through Eukaryotic Initiation Factor Alpha (eIF2α). Blood. 110: 1814-1814. DOI: 10.1182/Blood.V110.11.1814.1814 |
0.332 |
|
| 2006 |
Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer Cancer Biology and Therapy. 5: 1708-1713. PMID 17106249 DOI: 10.4161/Cbt.5.12.3468 |
0.366 |
|
| 2006 |
Halder J, Kamat AA, Landen CN, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Focal adhesion kinasetargeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy Clinical Cancer Research. 12: 4916-4924. PMID 16914580 DOI: 10.1158/1078-0432.Ccr-06-0021 |
0.377 |
|
| 2006 |
Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, ... ... Lopez-Berestein G, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma Nature Medicine. 12: 939-944. PMID 16862152 DOI: 10.1038/Nm1447 |
0.383 |
|
| 2006 |
Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G, Camacho LH. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer. 106: 2437-44. PMID 16615096 DOI: 10.1002/Cncr.21854 |
0.303 |
|
| 2006 |
Day CP, Rau KM, Qiu L, Liu CW, Kuo HP, Xie X, Lopez-Berestein G, Hortobagyi GN, Hung MC. Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Therapy. 13: 706-19. PMID 16514421 DOI: 10.1038/sj.cgt.7700945 |
0.31 |
|
| 2006 |
Ozpolat B, Akar U, Kondo Y, Lopez-Berestein G. All-Trans-Retinoic Acid (ATRA) Induces Autophagy in Acute Promyelocytic Leukemia Cells. Blood. 108: 2012-2012. DOI: 10.1182/Blood.V108.11.2012.2012 |
0.374 |
|
| 2006 |
Akar U, Ozpolat B, Colburn N, Lopez-Berestein G. p38 MAPK Signaling Mediates Retinoic Acid-Induced Expression of a Novel Tumor Suppressor Protein Programmed Cell Death 4 (PDCD4) in Acute Promyelocytic Leukemia Cells. Blood. 108: 1942-1942. DOI: 10.1182/Blood.V108.11.1942.1942 |
0.396 |
|
| 2006 |
Ozpolat B, Akar U, Barria M, Lopez-Berestein G. PKCδ Regulates Eukaryotic Initiation Factor eIF2α through PKR during Retinoic Acid-Induced Myeloid Cell Differentiation. Blood. 108: 1928-1928. DOI: 10.1182/Blood.V108.11.1928.1928 |
0.376 |
|
| 2006 |
Yang L, Hamilton S, Ellis E, Sanguino A, Lopez-Berestein G, Boyd D. ZNF306, a novel zinc finger transcription factor, drives colon cancer progression – An alternate genetic pathway in tumor progression? European Journal of Cancer Supplements. 4: 6. DOI: 10.1016/J.Ejcsup.2006.04.010 |
0.38 |
|
| 2006 |
Sood AK, Thaker PH, Jennings N, Kamat AA, Han LY, Armaiz-Pena G, Lopez-Berestein G, Lutgendorf SK, Cole SW. Tumor cell β adrenergic receptor dependence for chronic stress effects on ovarian cancer growth Brain Behavior and Immunity. 20: 66-67. DOI: 10.1016/J.Bbi.2006.04.149 |
0.377 |
|
| 2005 |
Ozpolat B, Mehta K, Lopez-Berestein G. Regulation of a highly specific retinoic acid-4-hydroxylase (CYP26A1) enzyme and all-trans-retinoic acid metabolism in human intestinal, liver, endothelial, and acute promyelocytic leukemia cells. Leukemia & Lymphoma. 46: 1497-506. PMID 16194896 DOI: 10.1080/10428190500174737 |
0.312 |
|
| 2004 |
Ozpolat B, Tari AM, Mehta K, Lopez-Berestein G. Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells. Leukemia & Lymphoma. 45: 979-85. PMID 15291358 DOI: 10.1080/1042819031000151833 |
0.371 |
|
| 2004 |
Siwak DR, Tari AM, Lopez-Berestein G. Liposomal antisense oligonucleotides for cancer therapy. Methods in Enzymology. 387: 241-53. PMID 15172168 DOI: 10.1016/S0076-6879(04)87015-0 |
0.376 |
|
| 2004 |
Harris MN, Ozpolat B, Abdi F, Gu S, Legler A, Mawuenyega KG, Tirado-Gomez M, Lopez-Berestein G, Chen X. Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia. Blood. 104: 1314-23. PMID 15142884 DOI: 10.1182/Blood-2004-01-0046 |
0.357 |
|
| 2004 |
Ozpolat B, Tirado-Gomez M, Colburn NH, Lopez-Berestein G. All-trans-Retinoic acid (ATRA) and Arsenic Trioxide-Induced Expression and Regulation of Programmed Cell Death 4 (PDCD4) in Acute Promyelocytic Leukemia. Blood. 104: 886-886. DOI: 10.1182/Blood.V104.11.886.886 |
0.379 |
|
| 2003 |
Gutiérrez-Puente Y, Tari AM, Ford RJ, Tamez-Guerra R, Mercado-Hernandez R, Santoyo-Stephano M, Lopez-Berestein G. Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line. Leukemia & Lymphoma. 44: 1979-85. PMID 14738153 DOI: 10.1080/1042819031000099733 |
0.355 |
|
| 2003 |
Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R, Lopez-Berestein G. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. The Journal of Biological Chemistry. 278: 19995-20005. PMID 12644474 DOI: 10.1074/Jbc.M205865200 |
0.765 |
|
| 2002 |
Tari AM, Lim SJ, Hung MC, Esteva FJ, Lopez-Berestein G. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Oncogene. 21: 5224-32. PMID 12149644 DOI: 10.1038/Sj.Onc.1205660 |
0.425 |
|
| 2002 |
Gutiérrez-Puente Y, Zapata-Benavides P, Tari AM, López-Berestein G. Bcl-2-related antisense therapy. Seminars in Oncology. 29: 71-6. PMID 12138400 DOI: 10.1053/sonc.2002.34058 |
0.344 |
|
| 2002 |
Zapata-Benavides P, Tuna M, Lopez-Berestein G, Tari AM. Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation. Biochemical and Biophysical Research Communications. 295: 784-90. PMID 12127961 DOI: 10.1016/S0006-291X(02)00751-9 |
0.416 |
|
| 2002 |
Ozpolat B, Mehta K, Tari AM, Lopez-Berestein G. all-trans-Retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia. American Journal of Hematology. 70: 39-47. PMID 11994980 DOI: 10.1002/Ajh.10099 |
0.343 |
|
| 2002 |
Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood. 99: 3461-4. PMID 11964319 DOI: 10.1182/Blood.V99.9.3461 |
0.334 |
|
| 2001 |
Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, ... ... Lopez-Berestein G, et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial Journal of Clinical Oncology. 19: 3422-3433. PMID 11454891 DOI: 10.1200/Jco.2001.19.14.3422 |
0.411 |
|
| 2000 |
Lim SJ, Lopez-Berestein G, Hung MC, Lupu R, Tari AM. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells. Oncogene. 19: 6271-6. PMID 11175341 DOI: 10.1038/Sj.Onc.1204014 |
0.394 |
|
| 2000 |
Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, López-Berestein G, Andreeff M. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins Blood. 95: 3929-3938. DOI: 10.1182/Blood.V95.12.3929 |
0.351 |
|
| 1999 |
Tari AM, Hung MC, Li K, Lopez-Berestein G. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene. 18: 1325-32. PMID 10022814 DOI: 10.1038/Sj.Onc.1202422 |
0.401 |
|
| 1999 |
Ueno NT, Xia W, Tucker SD, Zhang S, Lopez-Berestein G, Huang L, Hung M-. Issues in the development of gene therapy: preclinical experiments in E1A gene delivery. Oncology Reports. 6: 257-262. DOI: 10.3892/Or.6.2.257 |
0.327 |
|
| 1998 |
Hortobagyi GN, Hung MC, Lopez-Berestein G. A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. Human Gene Therapy. 9: 1775-98. PMID 9721088 DOI: 10.1089/HUM.1998.9.12-1775 |
0.31 |
|
| 1998 |
Tormo M, Tari AM, McDonnell TJ, Cabanillas F, Garcia-Conde J, Lopez-Berestein G. Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation. Leukemia & Lymphoma. 30: 367-79. PMID 9713967 DOI: 10.3109/10428199809057548 |
0.339 |
|
| 1997 |
Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, Lopez-Berestein G, Lozano G, Sarkiss M, McDonnell TJ. Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene. 15: 2767-72. PMID 9419967 DOI: 10.1038/Sj.Onc.1201464 |
0.312 |
|
| 1997 |
Tari AM, Arlinghaus R, Lopez-Berestein G. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells. Biochemical and Biophysical Research Communications. 235: 383-8. PMID 9199202 DOI: 10.1006/Bbrc.1997.6791 |
0.34 |
|
| 1997 |
Xing X, Liu V, Xia W, Stephens LC, Huang L, Lopez-Berestein G, Hung MC. Safety studies of the intraperitoneal injection of E1A--liposome complex in mice. Gene Therapy. 4: 238-43. PMID 9135737 DOI: 10.1038/Sj.Gt.3300376 |
0.313 |
|
| 1997 |
Tari A, Khodadadian M, Ellerson D, Deisseroth A, Lopez-Berestein G. Liposomal delivery of oligodeoxynucleotides. Leukemia & Lymphoma. 21: 93-7. PMID 8907275 DOI: 10.3109/10428199609067585 |
0.355 |
|
| 1997 |
Tari AM, Lopez-Berestein G. Oligonucleotide Therapy for Hematological Malignancies Journal of Liposome Research. 7: 19-30. DOI: 10.3109/08982109709035479 |
0.327 |
|
| 1996 |
Vadiei K, Tucker SD, Lopez-Berestein G, Wasan KM. Nephroprotective mechanism(s) of pentoxifylline: Reduction of erythrocyte-mediated vascular congestion and inhibition of nitric oxide release Pharmacology and Toxicology. 78: 174-180. PMID 8882351 DOI: 10.1111/J.1600-0773.1996.Tb00200.X |
0.301 |
|
| 1994 |
Tari A, Tucker S, Deisseroth A, Lopez-Berestein G. Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia [see comments] Blood. 84: 601-607. DOI: 10.1182/Blood.V84.2.601.Bloodjournal842601 |
0.338 |
|
| 1984 |
Mehta R, Lopez-Berestein G, Hopfer R, Mills K, Juliano RL. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochimica Et Biophysica Acta. 770: 230-4. PMID 6696909 DOI: 10.1016/0005-2736(84)90135-4 |
0.303 |
|
| 1984 |
Lopez-Berestein G, Milas L, Hunter N, Mehta K, Hersh EM, Kurahara CG, Vandupas M, Eppstein DA. Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-O-stearoyl-N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine. Clinical & Experimental Metastasis. 2: 127-37. PMID 6543694 DOI: 10.1007/Bf00052413 |
0.312 |
|
| Show low-probability matches. |